Treatment Options in Patients Suffering from Hemolytic-Uremic Syndrome: The Serbian Military Medical Academy Experience
By:
References
- 1. Lammle B, Kremer Hovinga A and Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005; 3: 1663-75.
- 2. Gasser C, Gautier E, Steck A, et al. Haemolytischuremische syndrome. Schweiz Med Wochenschr. 1955; 85: 905-9.
- 3. Karmali MA, Petric M, Lim C, et al. The association between idiopatic hemolytic-uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985; 151: 775-82.
- 4. Siegler RL. The hemolytic-uremic syndrome. Pediatr Clin North Am. 1995; 42: 1505-29.
- 5. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589-600.
- 6. Lowe E, Werner E. Thrombotic thrombocitopenic purpura and hemolytic-uremic syndrome in children and adolescents. Sem Thromb Haem. 2005; 31: 717-29.
- 7. Nolasco L, Turner N, Bernardo A, et al. Hemolytic-uremic syndrome-associated Shiga toxins promote endothelial- cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood. 2005; 106: 4199-209.
- 8. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001; 98: 2730-5.
- 9. Richards A, Kemp EJ, Liscewiski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad SCI USA. 2003; 100: 12966-71.
- 10. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment and outcome. Blood. 2006. E. Print.
- 11. Waiser J, Budde K, Rudolph B, et al. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis. 1999; 34: 556-9.
- 12. Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LA, Wetzels JF. Renal transplantation in patients with hemolytic- uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation. 2003; 76: 821-6.
- 13. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis. 2002; 40: E16.
- 14. Kiyakim A, Ozer C, Yildiz A, at al. Development of transplant renal artery thrombosis and signs of haemolytic- uremic syndrome following the change from cyclosporin to tacrolimus in a renal transplant patient. Nephrol Dial Transplant. 2004; 19: 2653-6.
- 15. Tsai HM: The molecular biology of thrombotic microangiopathy. Kidney Int. 2006; 70:16-23.
- 16. George JN, Nester CM:Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371: 654-666
- 17. Chua JS, Baelde HJ, Zandbergen M, et al. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. J Am Soc Nephrol. 2015; 26(9): 2239-47.
- 18. Nester CM, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement- mediated renal diseases. Curr Opin Pediatr. 2013; 25(2): 225-31.
- 19. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368(23): 2169-181.
- 20. Nishimura J-I, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Eng J Med. 2014; 370: 632-9.
- 21. Dhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost. 2015; 23(2): 175-180.
- 22. Vasu S, Wu H, Satoskar A, et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 2016; 51(9): 1241-1244
- 23. Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015; 66(1): 172-173
- 24. Wig S, Chan M, Thachil J, Bruce I, Barnes T. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology (Oxford). 2016; 55(2): 382-384
- 25. Deford CC, Reese JA. Schwartz LH, et al, Multiple major morbidities and increased mortality during long term follow-up after recovery from thrombic thrombocytopenic purpura. Blood. 2013; 122: 2023-9
- 26. Dejan Petrovic, Petar Canovic, Zeljko Mijailovic, Biljana Popovska Jovicic, Sasa Jacovic. Hemolitičko uremijski sindrom: etiopatogeneza, dijagnostika i osnovni principi lečenja. Med J (Krag). 2015; 49(2): 59-65.
- 27. Jokiranta TS. HUS and atypical HUS. Blood. 2017; 129(21): 2847-56.
Language: English
Page range: 237 - 242
Submitted on: Jun 27, 2019
Accepted on: Sep 16, 2019
Published on: Sep 20, 2022
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2022 Jelena Tadic, Mirjana Mijuskovic, Marijana Petrovic, Katarina Obrencevic, Brankica Terzic, Violeta Rabrenovic, Neven Vavic, Đoko Maksic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.